AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT) Files An 8-K Other EventsItem 8.01Other Events.
On June 12, 2017, Aimmune Therapeutics, Inc. (“Aimmune”) issued a press release providing an update on its ongoing Phase 3 PALISADE clinical trial for its lead product candidate, AR101 for the treatment of peanut allergy. The full text of the press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.
Item 9.01Financial Statements and Exhibits.
Reference is made to the Exhibit Index attached hereto.
About AIMMUNE THERAPEUTICS, INC. (NASDAQ:AIMT)
Aimmune Therapeutics, Inc., formerly Allergen Research Corporation, is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services. It has initiated Peanut Allergy Oral Immunotherapy Study of AR101 for Desensitization in Children and Adults (PALISADE), its Phase III registration trial of AR101. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation. For patients in the up-dosing phase of the AR101 treatment regimen, AR101 would be provided in a series of color coded pharmaceutical grade capsules of various dose levels.
